文献速递妇科

卵巢癌BRCA状态与铂类过敏反应:回顾性分析及系统综述

Hypersensitivity to platinum salts according to BRCA status in ovarian cancer: A retrospective analysis of clinical outcomes and systematic review of literature.
PubMed 文献 · Gynecol Oncol · 2021-04-22

该回顾性多中心研究纳入432例卵巢癌患者,评估已知BRCA状态下铂类过敏反应的发生率和严重程度。BRCA突变患者任何级别过敏反应发生率显著更高(18% vs 9%,p=0.019),且多变量分析显示BRCA突变与过敏反应风险升高相关(HR 1.84,95%CI 1.00-3.99,p=0.05),而接受聚乙二醇脂质体阿霉素(PLD)与风险降低相关(HR 0.03,95%CI 0.004-0.22,p=0.001)。系统综述证实BRCA突变患者过敏反应发生率更高,但系列间异质性显著。

要点

  • BRCA突变卵巢癌患者铂类过敏反应发生率显著高于野生型(18% vs 9%)。
  • BRCA突变与过敏反应风险升高独立相关(HR 1.84,95%CI 1.00-3.99)。
  • PLD暴露与过敏反应风险显著降低相关(HR 0.03,95%CI 0.004-0.22)。

核心结论

  • BRCA突变卵巢癌患者卡铂过敏反应发生率显著更高,且不能用药时长更长解释。
  • PLD在本系列中显示保护作用。
  • 系统综述证实BRCA突变患者过敏反应发生率更高,但异质性显著。

研究设计与样本

  • 回顾性分析意大利5个中心432例卵巢癌患者。
  • 同时进行系统综述和荟萃分析。

主要发现

  • BRCA突变患者任何级别过敏反应发生率18%,野生型9%(p=0.019)。
  • 过敏反应时间曲线显示风险随铂暴露时间延长而增加,BRCA突变者更明显。
  • 多变量分析:BRCA突变与过敏反应风险升高相关(HR 1.84,95%CI 1.00-3.99,p=0.05)。
  • PLD暴露与过敏反应风险降低相关(HR 0.03,95%CI 0.004-0.22,p=0.001)。
  • 系统综述证实BRCA突变患者过敏反应发生率更高,但系列间异质性显著。

临床怎么用

  • 对BRCA突变卵巢癌患者应加强铂类过敏反应的监测和预警。
  • PLD暴露可能降低过敏反应风险,可作为临床决策参考。

局限性

  • 回顾性研究设计。
  • 系统综述中系列间异质性显著。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hypersensitivity reactions (HSRs) to platinum are an important issue in the treatment of patients (pts) with ovarian cancer (OC). Germline BRCA mutations have been proposed as a risk factor. We aimed at evaluating the incidence and severity of HSRs to platinum in OC pts. with known BRCA status. PATIENTS AND METHODS: We retrospectively analyzed 432 pts. from 5 Italian Centers. In addition, we performed a systematic review and meta-analysis of published series. RESULTS: Four hundred nine pts. received at least one prior platinum-based treatment line: 314 were BRCA wild type (77%) and 95 were BRCA mutated (23%). There was no statistical difference in exposure to platinum. Incidence of any grade HSRs was higher among BRCA mutated pts. [9% vs 18%, p = 0.019] and the time-to-HSRs curves show that the risk increases with the duration of platinum exposure, in BRCA mutated pts. more than in BRCA wild type. A multivariable analysis showed that harboring a germline BRCA mutation was related to a higher incidence of HSRs (HR: 1.84, 95% CI 1.00-3.99, p = 0.05) while having received pegylated liposomal doxorubicin (PLD) was related to a lower incidence of HSRs (HR: 0.03 95% CI 0.004-0.22, p = 0.001). The systematic review confirmed the higher incidence of HSRs in BRCA mutated pts., though heterogeneity among series was significant. CONCLUSIONS: In OC pts. with BRCA mutations, there is a significantly higher incidence of HSRs to carboplatin, not justified by longer drug exposure. On the other hand, PLD exerted a protective role in our series.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Giannone G, Scotto G, Katsaros D, et al. Hypersensitivity to platinum salts according to BRCA status in ovarian cancer: A retrospective analysis of clinical outcomes and systematic review of literature. Gynecol Oncol. 2021. PMID: 33896588. doi:10.1016/j.ygyno.2021.04.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。